Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia

Copland, M. (2009) Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia. Future Oncology, 5(4), pp. 455-458. (doi:10.2217/FON.09.16)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.2217/FON.09.16

Abstract

Evaluation of: Mullighan CG, Su X, Zhang J et al: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470-480 (2009). Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood and despite impressive remission rates, approximately 20% of children with ALL relapse with disease that is often difficult to treat. Recently, genome-wide analysis has identified recurring genetic alterations in B-cell ALL, including mutation of PAX5 and deletions of IKZF1, IKZF3, E2A, EBF and LEF1. This large clinical study evaluates the prognostic impact of these genetic abnormalities in two independent cohorts of children with B-cell progenitor ALL and identifies deletion of IKZF1 (which encodes the lymphoid transcription factor Ikaros) as a predictor of poor outcome. This finding demonstrates the importance of IKZF1 status in pediatric ALL, and provides strong supporting evidence for its inclusion in pediatric ALL risk stratification for treatment protocols.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Copland, Professor Mhairi
Authors: Copland, M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Future Oncology
Publisher:Future Medicine Ltd.
ISSN:1479-6694
ISSN (Online):1744-8301
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
354131Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)Mhairi CoplandMedical Research Council (MRC)G84/6317Institute of Cancer Sciences